1
|
Kayabasi C, Yilmaz Susluer S, Balci Okcanoglu T, Ozmen Yelken B, Mutlu Z, Goker Bagca B, Caliskan Kurt C, Saydam G, Durmuskahya C, Kayalar H, Ozbilgin A, Biray Avci C, Gunduz C. Origanum Sipyleum Methanol Extract in Combination with Ponatinib Shows Synergistic anti-Leukemic Activities on Chronic Myeloid Leukemia Cells. Nutr Cancer 2022; 74:3679-3691. [PMID: 35608652 DOI: 10.1080/01635581.2022.2077969] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Abstract
Origanum sipyleum is used in folk medicine due to its anti-inflammatory, antimicrobial, and antioxidant properties. Ponatinib, an effective tyrosine kinase inhibitor in the treatment of chronic myeloid leukemia (CML), has severe side effects. Thus, we aimed to determine a novel herbal combination therapy that might not only increase the anti-leukemic efficacy but also reduce the dose of ponatinib in targeting CML cells. Origanum sipyleum was extracted with methanol (OSM), and secondary metabolites were determined by phytochemical screening tests. The cytotoxic effects of OSM on K562 cells were measured by WST-1 assay. Median-effect equation was used to analyze the combination of ponatinib and OSM (p-OSM). Apoptosis, proliferation, and cell-cycle were investigated by flow-cytometry. Cell-cycle-related gene expressions were evaluated by qRT-PCR. OSM that contains terpenoids, flavonoids, tannins, and anthracenes exhibited cytotoxic effects on K562 cells. The median-effect of p-OSM was found as synergistic; OSM reduced the ponatinib dose ∼5-fold. p-OSM elevated the apoptotic and anti-proliferative activity of ponatinib. Consistently, p-OSM blocked cell-cycle progression in G0/G1, S phases accompanied by regulations in TGFB2, ATR, PP2A, p18, CCND1, CCND2, and CCNA1 expressions. OSM enhanced the anti-leukemic activity of ponatinib synergistically via inducing apoptosis, suppressing proliferation, and cell-cycle. As a result, OSM might offer a potential strategy for treating patients with CML.
Collapse
Affiliation(s)
- Cagla Kayabasi
- Faculty of Medicine, Medical Biology Department, Ege University, Izmir, Turkey
| | | | | | - Besra Ozmen Yelken
- Faculty of Medicine, Department of Medical Biology, Izmir Bakircay University, Izmir, Turkey
| | - Zeynep Mutlu
- Faculty of Medicine, Medical Biology Department, Ege University, Izmir, Turkey
| | - Bakiye Goker Bagca
- Faculty of Medicine, Department of Medical Biology, Aydın Adnan Menderes University, Aydın, Turkey
| | - Cansu Caliskan Kurt
- Faculty of Medicine, Medical Biology Department, Ege University, Izmir, Turkey
| | - Guray Saydam
- Faculty of Medicine, Internal Medicine Department, Division of Hematology, Ege University, Izmir, Turkey
| | - Cenk Durmuskahya
- Faculty of Forestry, Department of Forest Engineering, Izmir Katip Celebi University, Izmir, Turkey
| | - Husniye Kayalar
- Faculty of Pharmacy, Department of Pharmacognosy, Ege University, Izmir, Turkey
| | - Ahmet Ozbilgin
- Faculty of Medicine, Department of Parasitology, Celal Bayar University, Manisa, Turkey
| | - Cigir Biray Avci
- Faculty of Medicine, Medical Biology Department, Ege University, Izmir, Turkey
| | - Cumhur Gunduz
- Faculty of Medicine, Medical Biology Department, Ege University, Izmir, Turkey
| |
Collapse
|
2
|
Kayabasi C, Caner A, Yilmaz Susluer S, Balci Okcanoglu T, Ozmen Yelken B, Asik A, Mutlu Z, Caliskan Kurt C, Goker Bagca B, Biray Avci C, Sahin F, Saydam G, Gunduz C. Comparative expression analysis of dasatinib and ponatinib-regulated lncRNAs in chronic myeloid leukemia and their network analysis. Med Oncol 2022; 39:29. [DOI: 10.1007/s12032-021-01629-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/09/2021] [Accepted: 12/13/2021] [Indexed: 10/19/2022]
|
3
|
Gunel NS, Birden N, Kurt CC, Bagca BG, Shademan B, Sogutlu F, Ozates NP, Avci CB. Effect of valproic acid on miRNAs affecting histone deacetylase in a model of anaplastic thyroid cancer. Mol Biol Rep 2021; 48:6085-6091. [PMID: 34374891 DOI: 10.1007/s11033-021-06616-2] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/31/2021] [Accepted: 07/29/2021] [Indexed: 12/15/2022]
Abstract
BACKGROUND Thyroid cancer is the most common malignant tumor of the endocrine system seen in the thyroid gland. More than 90% of thyroid cancers comprise papillary thyroid cancer (PTC) and follicular thyroid cancer (FTC). Although anaplastic thyroid carcinoma (ATC) accounts for less than 2% of thyroid cancer. But patients' lifespan after diagnosis is about 6 months. Surgical interventions, radioactive iodine use, and chemotherapy are not sufficient in the treatment of ATC, so alternative therapies are needed. METHODS AND RESULTS The WST-1 assay test was performed to evaluate the anti-proliferative effects of Valproic acid (VPA). Also, the effect of VPA on miRNAs affecting histone deacetylase was determined by Quantitative RT-PCR. In the SW1736 cell line, IC50 dose for VPA was found 1.6 mg/ml. In our study, the level of oncogenic genes expression in cells treated with VPA, including miR-184, miR-222-5p, miR-124-3p, and miR-328-3p, decreased. Also, the expression of tumor inhibitory genes including miR-323-5p, miR-182-5p, miR-138-5p, miR-217, miR-15a-5p, miR-29b-3p, miR-324-5p and miR-101-5p increased significantly. CONCLUSIONS VPA can ad-just countless gene expression patterns, including microRNAs (miRNAs), by targeting histone deacetylase (HDAC). However, further studies are required for more accurate results.
Collapse
Affiliation(s)
- Nur Selvi Gunel
- Department of Medical Biology, Ege University Medical School, Izmir, Turkey
| | - Nihal Birden
- Department of Medical Biology, Ege University Medical School, Izmir, Turkey
| | | | - Bakiye Goker Bagca
- Department of Medical Biology, Ege University Medical School, Izmir, Turkey
| | - Behrouz Shademan
- Department of Medical Biology, Ege University Medical School, Izmir, Turkey
| | - Fatma Sogutlu
- Department of Medical Biology, Ege University Medical School, Izmir, Turkey
| | | | - Cigir Biray Avci
- Department of Medical Biology, Ege University Medical School, Izmir, Turkey.
| |
Collapse
|
4
|
Ozdemir Kutbay N, Biray Avci C, Sarer Yurekli B, Caliskan Kurt C, Shademan B, Gunduz C, Erdogan M. Effects of metformin and pioglitazone combination on apoptosis and AMPK/mTOR signaling pathway in human anaplastic thyroid cancer cells. J Biochem Mol Toxicol 2020; 34:e22547. [PMID: 32589349 DOI: 10.1002/jbt.22547] [Citation(s) in RCA: 17] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/03/2020] [Revised: 04/28/2020] [Accepted: 05/29/2020] [Indexed: 02/06/2023]
Abstract
Anaplastic cancer constitutes 1% of thyroid cancers, and it is one of the most aggressive cancers. Treatment options are external radiation therapy and/or chemotherapy. The success rate with these treatment modalities is not satisfactory. We aimed to evaluate the effects of metformin (MET) and pioglitazone (PIO) combination on apoptosis and AMP-activated protein kinase/mammalian target of rapamycin (mTOR) signaling pathway in human anaplastic thyroid cancer cells. In this study, we evaluated the effects of MET and PIO individually and the combination of the two drugs on the cellular lines SW1736 and C643 ATC. Genes contained in the mTOR signaling pathway were examined using human mTOR Signalization RT2 Profiler PCR Array. In C643 and SW1736 cell lines, IC50 doses of MET and PIO were found out as 17.69 mM, 11.64 mM, 27.12 µM, and 23.17 µM. Also, the combination of MET and PIO was determined as an additive according to isobologram analyses. We have found the downregulation of the expression levels of oncogenic genes: AKT3, CHUK, CDC42, EIF4E, HIF1A, IKBKB, ILK, MTOR, PIK3CA, PIK3CG, PLD1, PRKCA, and RICTOR genes, in the MET and PIO combination-treated cells. In addition, expression levels of tumor suppressor genes, DDIT4, DDIT4L, EIF4EBP1, EIF4EBP2, FKBP1A, FKBP8, GSK3B, MYO1C, PTEN, ULK1, and ULK2, were found to have increased significantly. The MET + PIO combination was first applied to thyroid cancer cells, and significant reductions in the level of oncogenic genes were detected. The decreases, particularly, in AKT3, DEPTOR, EIF4E, ILK, MTOR, PIK3C, and PRKCA expressions indicate that progression can be prevented in thyroid cancer cells and these genes could be selected as therapeutic targets.
Collapse
Affiliation(s)
- Nilufer Ozdemir Kutbay
- Department of Endocrinology, Faculty of Medicine, Celal Bayar University, Manisa, Turkey
| | - Cigir Biray Avci
- Department of Medical Biology, Ege University Medical School, Izmir, Turkey
| | - Banu Sarer Yurekli
- Department of Endocrinology, Ege University Medical School, Izmir, Turkey
| | | | - Behrouz Shademan
- Department of Medical Biology, Ege University Medical School, Izmir, Turkey
| | - Cumhur Gunduz
- Department of Medical Biology, Ege University Medical School, Izmir, Turkey
| | - Mehmet Erdogan
- Department of Endocrinology, Ege University Medical School, Izmir, Turkey
| |
Collapse
|
5
|
Yurt F, Ocakoglu K, Er O, Soylu HM, Ince M, Avci CB, Kurt CC, Sarı FA, Colak SG, Gunduz C. Evaluation of photodynamic therapy and nuclear imaging potential of subphthalocyanine integrated TiO2 nanoparticles in mammary and cervical tumor cells. J PORPHYR PHTHALOCYA 2019. [DOI: 10.1142/s1088424619500639] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
Abstract
This study, subphthalocyanines (SubPc) and SubPc integrated TiO2 nanoparticles (SubPc-TiO[Formula: see text] were synthesized as novel photosensitizers. Their PDT effects were evaluated. Furthermore, nuclear imaging potential of [Formula: see text]I-labelled SubPc/SubPc-TiO2 were examined in mouse mammary carcinoma (EMT6) and cervix adenocarcinoma (HeLa) cell lines. The uptake results show that SubPc labelled with [Formula: see text]I radionuclide ([Formula: see text]I-SubPc) in EMT6 and HeLa cell lines was found to be approximately the same as in the WI38 cell line. However, the uptake values of SubPc-TiO2 labelled with [Formula: see text]I ([Formula: see text]I-SubPc-TiO[Formula: see text] in EMT6 and HeLa cell lines were determined to be two times higher than in the WI38 cell line. In other words, the target/non-target tissue ratio was identified as two in the EMT6 and HeLa cell lines. [Formula: see text]I-SubPc-TiO2 is promising for imaging or treatment of breast and cervix tumors. In vitro photodynamic therapy studies have shown that SubPc and SubPc-TiO2 are suitable agents for PDT. In addition, SubPc-TiO2 has higher phototoxicity than SubPc. As a future study, in vivo experiments will be held and performed in tumor-bearing nude mice.
Collapse
Affiliation(s)
- Fatma Yurt
- Department of Nuclear Applications, Institute of Nuclear Science, Ege University, Bornova, 35100, Izmir, Turkey
| | - Kasim Ocakoglu
- Department of Energy Systems Engineering, Faculty of Technology, Tarsus University, TR33400, Tarsus, Turkey
| | - Ozge Er
- Department of Nuclear Applications, Institute of Nuclear Science, Ege University, Bornova, 35100, Izmir, Turkey
| | - Hale Melis Soylu
- Department of Biomedical Technology, Institute of Science, Ege University, Bornova, 35100, Izmir, Turkey
| | - Mine Ince
- Department of Energy Systems Engineering, Faculty of Technology, Tarsus University, TR33400, Tarsus, Turkey
| | - Cıgır Biray Avci
- Department of Medical Biology, Faculty of Medicine, Ege University, Bornova, 35100, Izmir, Turkey
| | - Cansu Caliskan Kurt
- Department of Medical Biology, Faculty of Medicine, Ege University, Bornova, 35100, Izmir, Turkey
| | - Fatma Aslıhan Sarı
- Advanced Technology Research & Application Center, Mersin University, Ciftlikkoy Campus, TR33343, Yenisehir, Mersin, Turkey
| | - Suleyman Gokhan Colak
- Advanced Technology Research & Application Center, Mersin University, Ciftlikkoy Campus, TR33343, Yenisehir, Mersin, Turkey
| | - Cumhur Gunduz
- Department of Medical Biology, Faculty of Medicine, Ege University, Bornova, 35100, Izmir, Turkey
| |
Collapse
|
6
|
Yurt F, Sarı FA, Ince M, Colak SG, Er O, Soylu HM, Kurt CC, Avci CB, Gunduz C, Ocakoglu K. Photodynamic therapy and nuclear imaging activities of SubPhthalocyanine integrated TiO2 nanoparticles. J Photochem Photobiol A Chem 2018. [DOI: 10.1016/j.jphotochem.2018.08.004] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
7
|
Yurt F, Ocakoglu K, Ince M, Colak SG, Er O, Soylu HM, Gunduz C, Biray Avci C, Caliskan Kurt C. Photodynamic therapy and nuclear imaging activities of zinc phthalocyanine-integrated TiO2
nanoparticles in breast and cervical tumors. Chem Biol Drug Des 2017; 91:789-796. [DOI: 10.1111/cbdd.13144] [Citation(s) in RCA: 22] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/03/2017] [Revised: 09/07/2017] [Accepted: 11/01/2017] [Indexed: 12/15/2022]
Affiliation(s)
- Fatma Yurt
- Department of Nuclear Applications; Institute of Nuclear Science; Ege University; Izmir Turkey
| | - Kasim Ocakoglu
- Advanced Technology Research & Application Center; Mersin University; Mersin Turkey
- Department of Energy Systems Engineering; Faculty of Tarsus Technology; Mersin University; Mersin Turkey
| | - Mine Ince
- Department of Energy Systems Engineering; Faculty of Tarsus Technology; Mersin University; Mersin Turkey
| | | | - Ozge Er
- Department of Nuclear Applications; Institute of Nuclear Science; Ege University; Izmir Turkey
| | - Hale Melis Soylu
- Department of Biomedical Technology; Institute of Science; Ege University; Izmir Turkey
| | - Cumhur Gunduz
- Department of Medical Biology; Faculty of Medicine; Ege University; Izmir Turkey
| | - Cıgır Biray Avci
- Department of Medical Biology; Faculty of Medicine; Ege University; Izmir Turkey
| | - Cansu Caliskan Kurt
- Department of Medical Biology; Faculty of Medicine; Ege University; Izmir Turkey
| |
Collapse
|
8
|
Yurt F, Ince M, Colak SG, Ocakoglu K, Er O, Soylu HM, Gunduz C, Avci CB, Kurt CC. Investigation of in vitro PDT activities of zinc phthalocyanine immobilised TiO 2 nanoparticles. Int J Pharm 2017; 524:467-474. [DOI: 10.1016/j.ijpharm.2017.03.050] [Citation(s) in RCA: 37] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/23/2017] [Revised: 03/21/2017] [Accepted: 03/23/2017] [Indexed: 12/21/2022]
|
9
|
Biray Avci C, Kurt CC, Tepedelen BE, Ozalp O, Goker B, Mutlu Z, Dodurga Y, Elmas L, Gunduz C. Zoledronic acid induces apoptosis via stimulating the expressions of ERN1, TLR2, and IRF5 genes in glioma cells. Tumour Biol 2015; 37:6673-9. [PMID: 26646564 DOI: 10.1007/s13277-015-4519-3] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/28/2015] [Accepted: 11/25/2015] [Indexed: 11/28/2022] Open
Abstract
Glioblastoma multiforme (GBM) is the most common and aggressive brain tumor that affects older people. Although the current therapeutic approaches for GBM include surgical resection, radiotherapy, and chemotherapeutic agent temozolomide, the median survival of patients is 14.6 months because of its aggressiveness. Zoledronic acid (ZA) is a nitrogen-containing bisphosphonate that exhibited anticancer activity in different cancers. The purpose of this study was to assess the potential effect of ZA in distinct signal transduction pathways in U87-MG cells. In this study, experiments performed on U87-MG cell line (Human glioblastoma-astrocytoma, epithelial-like cell line) which is an in vitro model of human glioblastoma cells to examine the cytotoxic and apoptotic effects of ZA. IC50 dose of ZA, 25 μM, applied on U87-MG cells during 72 h. ApoDIRECT In Situ DNA Fragmentation Assay was used to investigate apoptosis of U87MG cells. The quantitative reverse transcription polymerase chain reaction (qRT-PCR) (LightCycler480 System) was carried out for 48 gene expression like NF-κB, Toll-like receptors, cytokines, and inteferons. Our results indicated that ZA (IC50 dose) increased apoptosis 1.27-fold in U87MG cells according to control cells. According to qRT-PCR data, expression levels of the endoplasmic reticulum-nuclei-1 (ERN1), Toll-like receptor 2 (TLR2), and human IFN regulatory factor 5 (IRF5) tumor suppressor genes elevated 2.05-, 2.08-, and 2.3-fold by ZA, respectively, in U87MG cells. Our recent results indicated that ZA have a key role in GBM progression and might be considered as a potential agent in glioma treatment.
Collapse
Affiliation(s)
- Cigir Biray Avci
- Medical Biology Department, Ege University Medical School, Bornova, Izmir, Turkey.
| | - Cansu Caliskan Kurt
- Medical Biology Department, Ege University Medical School, Bornova, Izmir, Turkey
| | - Burcu Erbaykent Tepedelen
- Department of Molecular Biology and Genetics, Avrasya University Faculty of Science and Letters, Trabzon, Turkey
| | - Ozgun Ozalp
- Medical Biology Department, Ege University Medical School, Bornova, Izmir, Turkey
| | - Bakiye Goker
- Medical Biology Department, Ege University Medical School, Bornova, Izmir, Turkey
| | - Zeynep Mutlu
- Medical Biology Department, Ege University Medical School, Bornova, Izmir, Turkey
| | - Yavuz Dodurga
- Medical Biology Department, Pamukkale University Medical School, Denizli, Turkey
| | - Levent Elmas
- Medical Biology Department, Pamukkale University Medical School, Denizli, Turkey
| | - Cumhur Gunduz
- Medical Biology Department, Ege University Medical School, Bornova, Izmir, Turkey
| |
Collapse
|
10
|
Bagca BG, Ozalp O, Kurt CC, Mutlu Z, Saydam G, Gunduz C, Avci CB. Ruxolitinib induces autophagy in chronic myeloid leukemia cells. Tumour Biol 2015; 37:1573-9. [PMID: 26298727 DOI: 10.1007/s13277-015-3947-4] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/07/2015] [Accepted: 08/17/2015] [Indexed: 12/22/2022] Open
Abstract
Ruxolitinib is the first agent used in myelofibrosis treatment with its potent JAK2 inhibitory effect. In this novel study, we aimed to discover the anti-leukemic effect of ruxolitinib in K-562 human chronic myeloid leukemia cell line compared to NCI-BL 2171 human healthy B lymphocyte cell line. Cytotoxic effect of ruxolitinib was determined by using WST-1 assay. IC50 values for K-562 and NCI-BL 2171 cell lines were defined as 20 and 23.6 μM at the 48th hour, respectively. Autophagic effects of ruxolitinib were detected by measuring LC3B-II protein formation. Ruxolitinib induced autophagic cell death in K-562 and NCI-BL 2171 cell lines 2.11- and 1.79-fold compared to control groups, respectively. To determine the autophagy-related gene expression changes, total RNA was isolated from K-562 and NCI-BL 2171 cells treated with ruxolitinib and untreated cells as control group. Reverse transcription procedure was performed for cDNA synthesis, and gene expressions were shown by RT-qPCR. Ruxolitinib treatment caused a notable decrease in expression of AKT, mTOR, and STAT autophagy inhibitor genes in K-562 cells, contrariwise control cell line. Ruxolitinib is a promising agent in chronic myeloid leukemia treatment by blocking JAK/STAT pathway known as downstream of BCR-ABL and triggering autophagy. This is the first study that reveals the relationship between ruxolitinib and autophagy induction.
Collapse
Affiliation(s)
- Bakiye Goker Bagca
- Department of Medical Biology, School of Medicine, Ege University, Izmir, Turkey.
| | - Ozgun Ozalp
- Department of Medical Biology, School of Medicine, Ege University, Izmir, Turkey
| | - Cansu Caliskan Kurt
- Department of Medical Biology, School of Medicine, Ege University, Izmir, Turkey
| | - Zeynep Mutlu
- Department of Medical Biology, School of Medicine, Ege University, Izmir, Turkey
| | - Guray Saydam
- Department of Hematology, School of Medicine, Ege University, Izmir, Turkey
| | - Cumhur Gunduz
- Department of Medical Biology, School of Medicine, Ege University, Izmir, Turkey
| | - Cigir Biray Avci
- Department of Medical Biology, School of Medicine, Ege University, Izmir, Turkey
| |
Collapse
|